GD2和GD3合酶：癌症治疗的新型药物靶点。
GD2 and GD3 synthase: novel drug targets for cancer therapy.
作者信息
Sphyris Nathalie, Sarkar Tapasree Roy, Battula Venkata L, Andreeff Michael, Mani Sendurai A
机构信息
Department of Translational Molecular Pathology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
Department of Leukemia; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
出版信息
Mol Cell Oncol. 2015 Mar 9;2(3):e975068. doi: 10.4161/23723556.2014.975068. eCollection 2015 Jul-Sep.
Our recent study suggests that targeting GD3 synthase (also known as ST8SIA1)-the rate-limiting enzyme in biosynthesis of the breast cancer stem cell marker GD2-abrogates metastasis and depletes the cancer stem cell populations within a tumor, thus providing an effective therapeutic strategy against metastatic breast cancers.
我们最近的研究表明，靶向GD3合酶（也称为ST8SIA1）——乳腺癌干细胞标志物GD2生物合成中的限速酶——可消除转移并耗尽肿瘤内的癌症干细胞群体，从而提供一种针对转移性乳腺癌的有效治疗策略。
Zotero 插件